Hypoglycaemia due to insulin therapy for the management of hyperkalaemia in hospitalised adults: A scoping review

Mogamat-Yazied Chothia, Toby Humphrey, Anel Schoonees, Usuf Mohamed, Ebrahim Chikte, Mogamat Razeen Davids

1 Division of Nephrology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, 2 Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 3 Centre for Evidence-based Health Care, Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, 4 Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

* yaziedc@sun.ac.za

Abstract

Introduction
Hyperkalaemia is a very common electrolyte disorder encountered in hospitalised patients. Although hypoglycaemia is a frequent complication of insulin therapy, it is often underappreciated. We conducted a scoping review of this important complication, and of other adverse effects, of the treatment of hyperkalaemia in hospitalised adults to map existing research on this topic and to identify any knowledge gaps.

Materials and methods
We followed the PRISMA-ScR guidelines. Studies were eligible for inclusion if they reported on any adverse effects in hospitalised patients ≥18-years-old, with hyperkalaemia receiving treatment that included insulin. All eligible research from 1980 to 12 October 2021 were included. We searched Medline (PubMed), Embase (Ovid), the Cochrane Library, CINHAL, Africa-Wide Information, Web of Science Core Collection, LILACS and Epistemonikos. The protocol was prospectively registered with the Open Science Framework (https://osf.io/x8cs9).

Results
Sixty-two articles were included. The prevalence of hypoglycaemia by any definition was 17.2% (95% CI 16.6–17.8%). The median timing of hypoglycaemia was 124 minutes after insulin administration (IQR 102–168 minutes). There were no differences in the prevalence of hypoglycaemia when comparing insulin dose (<10 units vs. ≥10 units), rate of insulin administration (continuous vs. bolus), type of insulin (regular vs. short-acting) or timing of insulin administration relative to dextrose. However, lower insulin doses were associated with a reduced prevalence of severe hypoglycaemia (3.5% vs. 5.9%, P = 0.02). There was
no difference regarding prevalence of hypoglycaemia by dextrose dose (≤25 g vs. >25 g); however, prevalence was lower when dextrose was administered as a continuous infusion compared with bolus administration (3.3% vs. 19.5%, P = 0.02). The most common predictor of hypoglycaemia was the pre-treatment serum glucose concentration (n = 13 studies), which ranged from < 5.6–7.8 mmol/L.

Conclusion
This is the first comprehensive review of the adverse effects following insulin therapy for hyperkalaemia. Hypoglycaemia remains a common adverse effect in hospitalised adults. Future randomised trials should focus on identifying the optimal regimen of insulin therapy to mitigate the risk of hypoglycaemia.

Introduction
Hyperkalaemia is a very common electrolyte disorder encountered in hospitalized patients [1] and, if left untreated, may result in life-threatening cardiac arrhythmias and death. The emergency treatment of hyperkalaemia includes shifting potassium into cells using intravenous insulin, with dextrose added before, with or after insulin administration to prevent hypoglycaemia.

Hypoglycaemia is a frequent complication of insulin therapy, but this serious adverse effect has not yet been systematically studied and is probably under-appreciated by most clinicians. In published reports, the proportion of patients who develop hypoglycaemia is as high as 75% [2]. Hypoglycaemia has been reported to occur up to six hours following insulin treatment and therefore frequent monitoring of the serum glucose concentration is needed to detect this serious complication and prevent it from causing neurological damage [3].

Many different treatment regimens have been proposed, which have variable effects on the serum potassium concentration (K⁺) and the risk of hypoglycaemia. Insulin can either be administered as an intravenous bolus or as a continuous infusion [2, 4]. Regardless of the regimen, insulin remains the most effective non-dialytic method for reducing serum K⁺, with average reductions of approximately 1.0 mmol/L at one hour [2, 4]. One common regimen involves the intravenous bolus administration of 10 units of insulin together with 25 g of dextrose (often as 50 ml of 50% dextrose water). The insulin concentrations needed to shift potassium into cells remain above the threshold concentration only transiently; however, it remains high enough to lower blood glucose (glycaemic concentrations) for a longer period, increasing the risk of hypoglycaemia [5].

Most of the studies on which the recommended treatment regimens are based have been performed in small groups of patients with kidney failure who are being treated with chronic haemodialysis [2, 4]. Most studies used 25 g of dextrose, with the prevalence of hypoglycaemia ranging from 7% to 75% [2]. The risk for hypoglycaemia appears to increase when using smaller doses of dextrose and in patients with kidney failure. Poor kidney function increases the half-life of insulin, resulting in hypoglycaemia which typically occurs 1–3 hours after insulin administration [6, 7]. Insulins with shorter half-lives, such as lispro and aspart, may reduce the risk of hypoglycaemia in those patients with kidney disease [8]. Patients with diabetes mellitus or higher pre-treatment blood glucose concentrations have a reduced risk of hypoglycaemia [9, 10].
Given the seriousness and the apparent high frequency of hypoglycaemia following insulin therapy, and the fact that this has not been comprehensively studied, we conducted a scoping review of this important complication, and of other adverse effects of the treatment of hyperkalaemia.

**Objectives**

We conducted a scoping review to map existing research on this topic and to identify any knowledge gaps. A hybrid approach was used. This included a confirmatory approach for known complications such as hypoglycaemia, as well as an exploratory approach where the included studies were screened for less well-known or unexpected complications.

The following research questions were investigated:

1. What are the reported adverse effects of insulin therapy during the emergency treatment of hyperkalaemia?
2. What is the prevalence of hypoglycaemia?
3. Have there been any other adverse effects reported?
4. What is the timing of adverse effects following therapy?
5. Have studies pre-specified surveillance for adverse effects or was the detection and reporting of adverse effects opportunistic?
6. What are the factors associated with a higher or lower risk of hypoglycaemia? We focused on the doses of insulin and dextrose used, the sequence of administration, the presence of diabetes, and pre-treatment glucose concentrations.

**Materials and methods**

**Protocol and registration**

We followed the Preferred Reporting Items for Systematic Reviews and Meta-analysis–Scoping Reviews (PRISMA-ScR) (S1 Checklist). The final protocol was registered prospectively with the Open Science Framework in September 2021 (https://osf.io/x8cs9/).

**Eligibility criteria**

Research articles were eligible for inclusion if they reported any adverse effects, particularly hypoglycaemia, in adult patients (at least 18 years old), with hyperkalaemia receiving treatment that included insulin therapy. We included randomised controlled trials, prospective and retrospective cohort studies, prospective experimental cross-over studies, case-control studies, cross-sectional studies, and case series. Existing systematic reviews were also included. We excluded studies in paediatric populations, patients not treated in hospital, animal studies and case reports (S1 Table).

**Information sources**

To identify relevant research, we searched the following bibliographic databases: Medline (PubMed), Embase (Ovid), the Cochrane Library (Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews), CINAHL (EBSCOhost), Africa-Wide Information (EBSCOhost), Web of Science Core Collection (specifically Science Citation Index Expanded, Social Sciences Citation Index, Conference Proceedings Citation Index (Clarivate)), LILACS (Virtual Health Library) and Epistemonikos. The search strategy was tailored to each
database, which is available in supporting information. All eligible research reports from 1980 to 12 October 2021, regardless of language, were included. The search strategy was performed by one of the authors (AS), an information specialist at Stellenbosch University. We also searched the conference proceedings of major nephrology congresses, specifically the American Society of Nephrology’s Kidney Week, the International Society of Nephrology’s World Congress of Nephrology and the European Renal Association-European Dialysis and Transplant Association congress, during the prior 3 years. The reference lists of retrieved publications were also hand-searched for additional relevant articles. A comprehensive search strategy can be found in S2 Table.

Selection of eligible research
The deduplicated search yield was imported into Rayyan screening software (https://rayyan.ai/). Two reviewers (MYC and TH) independently screened all the identified articles’ titles and abstracts. Conflicts were resolved by means of discussion and reaching consensus. For those selected to be potentially eligible, we obtained the full-text articles, and these were screened by a single reviewer (MYC). Reasons were provided where studies were excluded during the full-text screening stage (S3 Table).

Data extraction tool and data items
The first reviewer (MYC) developed and pilot-tested the data extraction tool with input from the other authors. The data that we extracted included the study design, type and year of publication, setting, sample size, demographics, comorbid and medication data, definitions of hyperkalaemia and hypoglycaemia, pre-treatment potassium and glucose concentrations, insulin regimen (type, dose, timing of administration and bolus vs. continuous infusion), dextrose administration where applicable (dose and bolus vs. continuous infusion), adverse events (timing, frequency, prespecified vs. opportunistic) and the utilisation of any other hyperkalaemia-specific therapies.

Critical appraisal of individual sources of evidence
The AMSTAR (Assessing the Methodological Quality of Systematic Reviews) 2 tool was used to grade the quality of included systematic reviews as either high, moderate, low, or critically low [11]. This was performed by two reviewers (MYC and AS) in a non-blinded manner.

Data synthesis
We provided a narrative synthesis of the extracted data. This was displayed in table format (S4 Table) and discussions were used to report similarities and differences between studies, as well as identifying gaps in the current evidence base.

Results
Selection of included research
The results of the search strategy and study selection are shown in Fig 1. We included a total of 62 research articles in the scoping review [2, 4, 9, 10, 12–69].

Characteristics of included research
Descriptive results of the primary studies are provided in Table 1. The most common study design was a retrospective cohort study (n = 38 studies); most studies were performed in
North America (n = 38 studies); three quarters (n = 48 studies) were conducted from 2015 to 2021, most of which were published articles (n = 45 studies); and the most frequent definitions used for hyperkalaemia and hypoglycaemia were K+ more than 5.0 mmol/L (n = 14 studies) and a glucose concentration less than or equal to 3.9 mmol/L (n = 40 studies), respectively. Table 2 provides a summary of the individual study characteristics. The complete data set can be found as supporting information as S7 Table.
Table 1. Summary of characteristics of included studies.

| Items                                | Summary |
|--------------------------------------|---------|
| Study design                         | N = 62  |
| Retrospective cohort                 | 38      |
| Prospective cohort                   | 9       |
| Systematic review                    | 5       |
| Randomised control trial             | 3       |
| Prospective experimental crossover   | 2       |
| Case series                          | 1       |
| Case-control                         | 1       |
| Not defined                          | 3       |
| Setting (continent)                  | N = 62  |
| North America                        | 38      |
| Europe                               | 11      |
| Asia                                 | 5       |
| Africa                               | 2       |
| Australia                            | 1       |
| Year of publication                  | N = 62  |
| 1988                                 | 2       |
| 1989                                 | 1       |
| 1990                                 | 1       |
| 1993                                 | 1       |
| 1996                                 | 1       |
| 1997                                 | 1       |
| 2001                                 | 1       |
| 2002                                 | 1       |
| 2005                                 | 1       |
| 2006                                 | 1       |
| 2012                                 | 1       |
| 2014                                 | 2       |
| 2015                                 | 3       |
| 2016                                 | 4       |
| 2017                                 | 7       |
| 2018                                 | 6       |
| 2019                                 | 11      |
| 2020                                 | 10      |
| 2021                                 | 7       |
| Type of publication                  | N = 62  |
| Published articles                   | 45      |
| Conference proceedings               | 17      |
| Range of sample size in studies      | N = 15363 |
| Minimum                              | 5       |
| Maximum                              | 1307    |
| Definitions for hyperkalaemia        | N = 57  |
| >5.0 mmol/L                          | 14      |
| ≥5.1 mmol/L                          | 5       |
| >5.3 mmol/L                          | 2       |
| >5.4 mmol/L                          | 1       |
| ≥5.5 mmol/L                          | 6       |

(Continued)
Characteristics and critical appraisal of included systematic reviews

We identified five systematic reviews (S5 Table) [2, 4, 67–69]. Two reviews were regarded as being of critically low quality (no registered protocol before commencement of the review could be identified or no list and justification for the exclusion of studies or did not perform a comprehensive search strategy) [2, 68], one review was of moderate quality (two non-critical domain findings) [69] and two of high quality [4, 67].

Synthesis of results

Summary of patient characteristics and pharmacological data. There was a total of 82 treatment arms among the 57 included primary studies, with 23 studies having two treatment arms, one having three treatment arms and 33 having a single treatment arm. Patient characteristics are summarised in Table 2. The total sample size was 15 363 patients. The mean [SD] age was 59.9 [7.4] years; most of the patients were male (n = 6 462 patients, n = 56 treatment arms), with a male-to-female ratio of 1.3:1; and the most frequent comorbidities were kidney failure (n = 5 351 patients) and diabetes mellitus (n = 3 575 patients). Renin-angiotensin-aldosterone system inhibitor use was reported in eight studies (n = 1 539 patients) (S1 Fig). Thirteen studies reported the use of chronic diabetic medication of which insulin therapy (n = 538 patients) was the most frequent (S2 Fig).

The data for insulin and dextrose use has been summarised in Table 2. Insulin dose was reported in 62 treatment arms. The dose could not be calculated for eight treatment arms because a dose range was reported for five treatment arms and an infusion rate (in units/kg/min)—without providing weight—was reported for three treatment arms. Regular insulin was most frequently prescribed (n = 47 treatment arms) at a median dose of 10 units [IQR 10–10 units]; insulin was administered as a bolus in most studies (n = 27 treatment arms) and was co-administered with dextrose in 26 treatment arms. The dextrose dose was available for 61 treatment arms. The dose could not be calculated for three treatment arms because a range was reported for two treatment arms and an infusion rate (mg/kg/min)—without providing weight—was reported for one treatment arm. The median dextrose dose was 25 g [IQR 25–40 g] and was most frequently administered as a bolus (n = 19 treatment arms).
Table 2. Summary of demographic, clinical and pharmacological data for primary included studies.

| Demographic and clinical data | Number of treatment arms, n = 82 |
|------------------------------|----------------------------------|
| Total sample size, n         | 81                               |
| Age (years), mean [SD]       | 65                               |
| Sex, n                       | 15 363                           |
| Male                         | 56                               |
| Not reported                 | 27                               |
| Male: Female ratio           | 56                               |
| Weight (kg), mean [SD]       | 31 78 [7.3]                      |
| BMI (kg/m²), mean [SD]       | 14 27.2 [2.7]                    |

Comorbidities, n

| Diabetes mellitus            | 46 3 575                          |
| Heart failure                | 2 43                              |
| Kidney transplant recipients | 2 111                             |
| Kidney failure               | 52 5 351                          |
| Acute kidney injury          | 18 1 003                          |
| Chronic kidney disease (non-dialysis) | 20 2 781                     |
| Chronic dialysis             | 42 2 254                          |

Pharmacological data

**Insulin**

| Overall average dose (units), median [IQR] | 62 10 [10–10] |
| <10 units, median [IQR]                  | 14 5.9 [5.0–8.7] |
| 5–10 units                               | 5 –           |
| ≥10 units, median [IQR]                  | 48 10 [10–10]  |

Type of insulin

| Regular                              | 47 –        |
| Short-acting                         | 5 –         |
| Timing                               | –           |
| Before dextrose                      | 3 –         |
| With dextrose                        | 26 –        |
| After dextrose                       | 8 –         |
| Infusion rate                        | –           |
| Bolus                                | 27 –        |
| Continuous                           | 9 –         |

Continuous infusion rate (min), mean [SD]

| Continuous infusion rate (min), mean [SD] | 9 105 [103] |

**Dextrose**

| Overall average dose (g), median [IQR] | 62 25 [25–40] |
| ≤25 g, median [IQR]                   | 40 25 [25–25] |
| >25 g, median [IQR]                   | 22 50 [40–50] |

Infusion rate, %

| Bolus                                | 19 –        |
| Continuous                           | 15 –        |

Infusion rate (min), median [IQR]

| Infusion rate (min), median [IQR]     | 15 22.5 [15–60] |

**Additional potassium-lowering therapies**

| Calcium salts                        | 17 –        |
| Furosemide                           | 21 –        |
| Sodium polystyrene sulphonate        | 21 –        |
| Salbutamol nebulisation              | 24 –        |

(Continued)
Additional hyperkalaemia therapies included calcium salts (n = 17 treatment arms), furosemide (n = 21 treatment arms), sodium polystyrene sulphonate (n = 21 treatment arms), salbutamol nebulisations (n = 24 treatment arms), intravenous sodium bicarbonate (n = 19 treatment arms) and dialysis (n = 4 treatment arms) (S3 Fig).

What were the reported adverse effects of insulin therapy during the emergency treatment of hyperkalaemia. Nearly all the primary studies reported prespecified adverse effects (n = 55) while one study reported opportunistic adverse effects [63], and another reported both prespecified and opportunistic adverse effects [21]. Hypoglycaemia was the prespecified adverse effect reported by all primary studies. The opportunistic adverse effects reported by a single study was pulmonary oedema (one patient) and burning/warm sensations in the infusion arm or over the chest when 100 mL of 50% dextrose was administered that promptly subsided once the infusion was complete (10 patients) [21].

What is the prevalence of hypoglycaemia. The prevalence of hypoglycaemia (by any definition) reported by the primary studies was 17.2% [95% CI 16.6–17.8%] while the prevalence of severe hypoglycaemia (by any definition) was 5.4% [95% CI 4.9–5.9%] (Table 3). Prevalence of hypoglycaemia by specific definitions have been summarised in Table 3. The prevalence of hypoglycaemia for retrospective (n = 55 treatment arms) and prospective (n = 22 treatment arms) studies were 17.3% [95% CI 16.7–17.9%] and 15.8% [95% CI 13.4–18.5%], respectively, P = 0.54. The reported prevalence of hypoglycaemia in the systematic reviews ranged from 16.8% to 20.9% (S5 Table).

What was the timing of hypoglycaemia. Forty-three primary studies reported the duration of monitoring for hypoglycaemia, of which half monitored up to six hours following the administration of insulin therapy (S4 Fig). The median timing of hypoglycaemia occurred at 124 minutes [IQR: 102–168 minutes].

What were the factors associated with higher or lower risk of hypoglycaemia. There were no differences in the prevalence of hypoglycaemia when comparing insulin dose (<10 units vs. ≥10 units), rate of insulin administration (continuous vs. bolus), type of insulin (regular vs. short-acting) or timing of insulin administration relative to dextrose (before vs. with

| Number of treatment arms, n = 82 |
|----------------------------------|
| Intravenous sodium bicarbonate   | 19 |
| Dialysis                         | 4  |

Table 3. Prevalence of hypoglycaemia and severe hypoglycaemia (by any definition and specified definitions).

| Prevalence of hypoglycaemia          | % [95% CI] |
|-------------------------------------|------------|
| By any definition                    | 17.2 [16.6–17.8] |
| By specific definitions              |            |
| <2.8 mmol/L                          | 8.1 [5.7–11.1] |
| <3.0 mmol/L                          | 8.6 [6.2–11.6] |
| <3.3 mmol/L                          | 10.0 [7.9–12.5] |
| <3.9 mmol/L                          | 16.9 [16.3–17.5] |

| Severe hypoglycaemia                |            |
| By any definition                    | 5.4 [4.9–5.9] |
| By specific definitions              |            |
| ≤2.2 mmol/L                          | 3.8 [3.2–4.4] |
| ≤2.8 mmol/L                          | 6.5 [5.8–7.3] |
vs. after dextrose) (Table 4). However, lower insulin doses were associated with reduced prevalence of severe hypoglycaemia [3.5% vs. 5.9%, P = 0.02]. There was no difference regarding the reduction in serum K+ with lower vs. standard/high insulin doses [-0.81 mmol/L vs. -0.90 mmol/L, respectively, P = 0.18] (S5 Fig).

There was no difference regarding the prevalence of hypoglycaemia by dextrose dose (<25 g vs. >25 g); however, prevalence was lower when dextrose was administered as a continuous infusion compared with bolus administration [3.3% vs. 19.5%, P = 0.02] (Table 4).

For comorbidities, the prevalence of hypoglycaemia was lower in treatment arms that reported this outcome in the sub-population of patients with diabetes (n = 12 treatment arms) compared to those without (n = 8 treatment arms), although this did not reach statistical significance [11.2% vs. 20.0%, P = 0.46] (S6 Fig). Also, the prevalence of hypoglycaemia was higher in treatment arms that reported this outcome in the sub-population of patients with kidney failure (n = 34 treatment arms) but was not statistically significant [19.6% vs. 10.2%, P = 0.70]. The prevalence was 22.7% for kidney transplant recipients.

Studies reporting additional hyperkalaemia therapies had lower prevalence of hypoglycaemia [14.3% vs. 18.3%, P = 0.03] (S7 Fig) as well as greater reductions in K+ [-1.0 mmol/L vs. -0.83 mmol/L, P = 0.03] when compared to studies where no additional therapies were used (S8 Fig).

Sixteen primary studies performed regression analysis [10, 12, 15, 23, 26, 29, 32, 34, 37, 46, 49, 53, 57, 59, 62, 65]. The most common predictors of hypoglycaemia were pre-treatment serum glucose concentration (n = 13 studies), insulin dose (n = 8 studies), kidney failure (n = 5 studies) and diabetes (n = 4 studies). Other predictors included weight/BMI, age, sex, and treatment in the emergency department (S6 Table).

### Table 4. Comparison of the prevalence of hypoglycaemia by insulin (dose, rate of infusion, type, and timing relative to dextrose) and dextrose (dose and rate of infusion).

| Insulin and dextrose | Prevalence of hypoglycaemia (%), median [IQR] | p-value | Prevalence of severe hypoglycaemia (%), mean [SD] | p-value |
|----------------------|-----------------------------------------------|---------|-----------------------------------------------|---------|
| **Insulin**          |                                               |         |                                               |         |
| Dose                 |                                               |         |                                               |         |
| <10 units            | 10.9 [8.7–19.5]                               | 0.26    | 3.5 [2.8]                                     | 0.03    |
| ≥10 units            | 17.5 [8.3–20.5]                               |         | 5.9 [2.6]                                     |         |
| Rate of infusion     |                                               |         |                                               |         |
| Bolus                | 15.8 [6.8–22.2]                               | 0.23    | 4.9 [3.4]                                     | 0.74    |
| Continuous           | 6.1 [0.0–20.0]                                |         | 4.0 [4.0]                                     |         |
| Type                 |                                               |         |                                               |         |
| Regular              | 14.9 [8.7–20.5]                               | 0.26    | 4.5 [3.0]                                     | 0.64    |
| Short-acting         | 8.3 [6.1–15.8]                                |         | 3.4 [3.1]                                     |         |
| Timing relative to dextrose |                     |         |                                               |         |
| Before               | 20.0 [2.1–75.0]                               | 0.68    | None                                          | 0.91    |
| With                 | 17.6 [3.3–28.6]                               |         | 4.2 [2.4]                                     |         |
| After                | 13.5 [3.4–21.1]                               |         | 4.0 [4.4]                                     |         |
| **Dextrose**         |                                               |         |                                               |         |
| Dose                 |                                               |         |                                               |         |
| ≤25g                 | 17.1 [8.7–20.9]                               | 0.52    | 5.5 [3.4]                                     | 0.19    |
| >25g                 | 12.5 [8.3–19.7]                               |         | 4.0 [2.9]                                     |         |
| Rate of infusion     |                                               |         |                                               |         |
| Bolus                | 19.5 [11.1–27.8]                              | 0.02    | 5.3 [3.4]                                     | 0.36    |
| Continuous           | 3.3 [0.0–20.0]                                |         | 3.2 [3.1]                                     |         |

https://doi.org/10.1371/journal.pone.0268395.t004
One systematic review that we judged to be of critically low quality, performed meta-analyses and reported that alternative insulin dosing (defined as < 10 units) had lower odds associated with hypoglycaemia and severe hypoglycaemia [68].

**Discussion**

This scoping review is the first comprehensive scoping review of hypoglycaemia and other adverse effects following the emergency management of hyperkalaemia. We identified 62 research articles, with most reporting on hypoglycaemia as a prespecified adverse effect and most performed during the past six years. The overall prevalence of hypoglycaemia for primary studies by any definition was 17.2% and ranged from 0% to 75%. This wide range may be due to differences in the definitions for hypoglycaemia, differences in the study populations and the insulin/dextrose regimens. For systematic reviews, the overall prevalence of hypoglycaemia had a narrow range (16.8% to 20.9%). Variation in the size of the total number of patients of included primary studies may have impacted on the observed prevalence with larger studies reporting the lowest prevalence. Another factor was the difference in the duration of monitoring for hypoglycaemia following insulin therapy which ranged from 60 minutes to 480 minutes. A study that only monitored for 60 minutes following insulin reported no episodes of hypoglycaemia [67]. However, since most systematic reviews only included prospective studies that actively monitored for hypoglycaemia, it is unlikely that episodes of hypoglycaemia were missed.

Hypoglycaemia occurred at an average of two hours following insulin therapy. It is recommended that patients with hyperkalaemia treated with insulin therapy should be monitored for up to six hours following therapy since the glucose lowering effect of insulin is prolonged in patients with kidney failure [3]. This finding is especially important since treatment is often administered in busy emergency departments where close monitoring for hypoglycaemia may be challenging.

The dose, type, rate of infusion and administration of insulin relative to dextrose were not associated with hypoglycaemia in our scoping review. However, a systematic review with meta-analysis that we judged to be of critically low quality reported a reduced prevalence of hypoglycaemia when lower doses of insulin were compared with standard doses [68]. Since there was no difference in efficacy regarding the reduction of the serum K+ with lower doses of insulin, and lower doses having a reduced risk of severe hypoglycaemia, it seems that lower doses of insulin (5 units or 0.1 units/kg) should be considered for the emergency management of hyperkalaemia.

Although a higher dextrose dose was not associated with a lower prevalence of hypoglycaemia, continuous infusion was. A theoretical regimen suggested that 60 g of 10% dextrose be infused over one hour [5]. This would require a volume of 600 mL. However, pulmonary oedema was described in a patient with kidney failure and hypertensive heart disease following 100 mL of 50% dextrose administered as a bolus [21]. Since hyperkalaemia frequently occurs in patients with kidney failure [1], decisions regarding the rate and volume of dextrose utilised should include the assessment of the patient’s volume and cardiac status.

We found that primary studies which included the use of additional hyperkalaemia therapies had a lower prevalence of hypoglycaemia. The reasons for this were unclear. There were no differences between studies that did and did not report additional therapies regarding pre-treatment serum K+, pre-treatment serum glucose concentrations, type, doses, or rate of infusion of insulin and dextrose, diabetes status and kidney failure. However, in systematic reviews, one study reported less episodes of hypoglycaemia when salbutamol nebulisations were added to insulin therapy [14], and another reported no episodes when variable
combinations of salbutamol and sodium bicarbonate were added to insulin [51]. Sympathetic stimulation by salbutamol may stimulate gluconeogenesis counteracting the hypoglycaemic effect of insulin.

The most common predictor of hypoglycaemia was a lower pre-treatment serum glucose concentration. This may explain why some primary studies identified diabetes status as having a reduced risk of hypoglycaemia [15, 23, 46, 49]. Other predictors included insulin dose and kidney failure. Although we found higher prevalence rates of hypoglycaemia in patients with kidney failure and lower rates in those with diabetes, they were not statistically significant; however, the total number of treatment arms included suggests that these analyses were likely underpowered. Therefore, awareness of the pre-treatment serum glucose concentration and kidney function may be important prior to prescribing insulin therapy as these factors may help to inform the prescription so that the risk of hypoglycaemia can be reduced.

Limitations

This scoping review has some limitations. Included studies with small sample sizes may have under- or overestimated hypoglycaemia prevalence. A few studies monitored for hypoglycaemia only up to 60 minutes. These studies may have underreported the prevalence of hypoglycaemia since this complication frequently occurs more than one hour following insulin therapy. Most of the studies were retrospective in design and hypoglycaemia was the only pre-specified adverse effect. Therefore, there may be underreporting of other opportunistic adverse effects. The accuracy of some of the serum glucose measurements at the defined threshold values may have affected the prevalence of hypoglycaemia, especially when bedside capillary blood glucose measurements were performed [70]. Insulin and dextrose doses were not explicitly reported by some primary studies.

Conclusions

This is the first comprehensive scoping review of the frequency of adverse effects following therapy with insulin for the emergency management of hyperkalaemia. Hypoglycaemia, the most concerning complication of this therapy, remains a common adverse effect but may be reduced by adapting the prescription of both insulin therapy. Most of the primary studies included in this review were retrospective in design; future randomised trials should focus on identifying the optimal regimen of insulin therapy to mitigate the risk of hypoglycaemia, while still effectively reducing K+, to inform treatment guidelines and clinical practice.

Supporting information

S1 Checklist. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist.

S1 Table. Inclusion and exclusion criteria.

S2 Table. Search strategy of databases.

S3 Table. List of excluded studies.

S4 Table. Individual primary study characteristics. *Kidney failure includes acute kidney injury, chronic kidney disease and end-stage kidney disease. †RCS, retrospective cohort study;
‡PCOS, Prospective cross-over study; §PCS, prospective cohort study; ‖RCT, Randomised control trial; ¶CC, case-control study; #CS, Case series; **K, Potassium.

S5 Table. Included systematic reviews.
(PDF)

S6 Table. Predictors of hypoglycaemia by primary studies that performed regression analysis. All predictors included were statistically significant, P<0.05.
(PDF)

S7 Table. Data set.
(XLS)

S1 Fig. Number of patients prescribed drugs associated with hyperkalaemia.
(TIF)

S2 Fig. Number of patients prescribed chronic anti-diabetic medication.
(TIF)

S3 Fig. Number of studies reporting additional hyperkalaemia therapies.
(TIF)

S4 Fig. Duration of monitoring for hypoglycaemia.
(TIF)

S5 Fig. Comparison of the average reduction in serum potassium concentration with <10 units vs. ≥10 units of insulin.
(TIF)

S6 Fig. Rates of hypoglycaemia by diabetic status.
(TIF)

S7 Fig. Rates of hypoglycaemia by additional hyperkalaemia therapies.
(TIF)

S8 Fig. Average reduction in serum potassium concentration by additional hyperkalaemia therapies.
(TIF)

Author Contributions

Conceptualization: Mogamat-Yazied Chothia, Usuf Mohamed Ebrahim Chikte, Mogamat Razeen Davids.

Data curation: Mogamat-Yazied Chothia, Toby Humphrey, Anel Schoonees.

Formal analysis: Mogamat-Yazied Chothia, Mogamat Razeen Davids.

Investigation: Mogamat-Yazied Chothia.

Methodology: Mogamat-Yazied Chothia, Toby Humphrey, Anel Schoonees, Usuf Mohamed Ebrahim Chikte, Mogamat Razeen Davids.

Project administration: Mogamat-Yazied Chothia.

Resources: Mogamat-Yazied Chothia.

Software: Mogamat-Yazied Chothia.
Supervision: Usuf Mohamed Ebrahim Chikte, Mogamat Razeen Davids.

Validation: Mogamat-Yazied Chothia, Toby Humphrey, Anel Schoonees, Usuf Mohamed Ebrahim Chikte.

Visualization: Mogamat-Yazied Chothia.

Writing – original draft: Mogamat-Yazied Chothia.

Writing – review & editing: Mogamat-Yazied Chothia, Toby Humphrey, Anel Schoonees, Usuf Mohamed Ebrahim Chikte, Mogamat Razeen Davids.

References

1. Humphrey T, Davids MR, Chothia M-Y, Pecoits-Filho R, Pollock C, James G. How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies. Clin Kidney J. 2021. https://doi.org/10.1093/ckj/sfab243 PMID: 35371465
2. Harel Z, Kamel KS. Optimal dose and method of administration of intravenous insulin in the management of emergency hyperkalaemia: a systematic review. PLoS One. 2016; 11(5):e0154963. https://doi.org/10.1371/journal.pone.0154963 PMID: 27148740
3. Alfonzo A, Soar J, MacTier R, Fox J, Shilliday I, Nolan J, et al. Clinical practice guidelines: treatment of acute hyperkalaemia in adults. UK Renal Association. 2020.
4. Batterink J, Cessford TA, Taylor RA. Pharmacological interventions for the acute management of hyperkalaemia in adults. Cochrane Database Syst Rev. 2015; 10:CD010344.
5. Sterns RH, Gieff M, Bernstein PL. Treatment of hyperkalaemia: something old, something new. Kidney Int. 2016; 89(3):546–54. https://doi.org/10.1016/j.kint.2015.11.018 PMID: 26880451
6. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab. 2008; 10(10):811–23. https://doi.org/10.1111/j.1463-1326.2007.00802.x PMID: 18248491
7. Blotta F, Badenes R, Lolli S, Belda FJ, Einav S, Roga S. Insulin infusion therapy in critical care patients: regular insulin vs short-acting insulin. A prospective, crossover, randomized, multicenter blind study. J Crit Care. 2015; 30(2):437.e1–e6. https://doi.org/10.1016/j.jcrc.2014.10.019 PMID: 25466315
8. Estep P, Erfle LD. Evaluation of hypoglycemia incidence and risk factors in patients treated with IV insulin aspart for hyperkalaemia. Endocrinol Diabetes Res. 2015; 3:1–4.
9. Apel J, Reuterkul S, Baldwin D. Hypoglycaemia in the treatment of hyperkalaemia with insulin in patients with end-stage renal disease. Clin Kidney J. 2014; 7(3):248–50. https://doi.org/10.1093/ckj/sfu026 PMID: 25852984
10. Coca A, Valencia AL, Bustamante J, Mendiluce A, Floege J. Hypoglycaemia following intravenous insulin plus glucose for hyperkalaemia in patients with impaired renal function. PLoS One. 2017; 12(2): e0172961. https://doi.org/10.1371/journal.pone.0172961 PMID: 28245289
11. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017; 358:j4008. https://doi.org/10.1136/bmj.j4008 PMID: 28935701
12. Aljabri A, Perona S, Alshibani M, Khoabrani M, Jarrell D, Patanwala AE. Blood glucose reduction in patients treated with insulin and dextrose for hyperkalaemia. Emerg Med J. 2020; 37(1):31–5. https://doi.org/10.1136/emermed-2019-208744 PMID: 31653693
13. Aljabri AM, Alsulami SA. Frequency of serum blood glucose monitoring after hyperkalaemia treatment using insulin and dextrose. J Taibah Univ Med Sci. 2021; 17(1):82–86. https://doi.org/10.1016/j.jtumed.2021.07.014 PMID: 35140569
14. Allon M, Copkney C, Albuterol and insulin for treatment of hyperkalaemia in hemodialysis patients. Kidney Int. 1990; 38(5):669–72. https://doi.org/10.1038/ki.1990.284 PMID: 22666701
15. Beltrami-Moreira M. Hypoglycaemia as an Adverse Event of Hyperkalaemia Treatment: Characteristics and Risk Factors. Endocrine Practice. 2020; 26:94.
16. Binz S, Konowitz NP, Bennett S, Miller J. The highest risk for hypoglycaemia after treatment for hyperkalaemia is in the emergency department. Available at: https://scholarlycommons.henryford.com/emergencymedicine_mtgabstracts/139/. Accessed February 10, 2022.
17. Blumberg A, Weidmann P, Shaw S, Gnädinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med. 1988; 85(4):507–12. https://doi.org/10.1016/s0002-9343(88)80086-x PMID: 3052050
18. Boughton CK, Dixon D, Goble E, Burridge A, Cox A, Noble-Bell G, et al. Preventing hypoglycaemia following treatment of hyperkalaemia in hospitalised patients. J Hosp Med. 2019; 14(5):284–7. https://doi.org/10.12788/jhm.3145 PMID: 30794138

19. Brown K Jr, Setji TL, Hale SL, Cooper A, Hong B, Herbst R, et al. Assessing the impact of an order panel using weight-based insulin and standardized monitoring of blood glucose for patients with hyperkalaemia. Am J Med Qual. 2018; 33(6):598–603. https://doi.org/10.1177/1062860618764610 PMID: 29553285

20. Chittineni C, Driver BE, Halverson M, Cole JB, Prekker ME, Pandey V, et al. Incidence and causes of iatrogenic hypoglycaemia in the emergency department. West J Emerg Med. 2019; 20(5):832–6. https://doi.org/10.5811/westjem.2019.7.42996 PMID: 31539342

21. Chothia M-Y, Halperin ML, Rensburg MA, Hassan MS, Davids MR. Bolus administration of intravenous glucose in the treatment of hyperkalaemia: a randomized controlled trial. Nephron Physiol. 2014; 126(1):1–8. https://doi.org/10.1159/000358836 PMID: 24576893

22. Coca A, Valencia A, Ferrer C, Sobrino A, Sanchez J, Bustamante J, et al. Human insulin vs aspart and incidence of hypoglycaemia in the management of hyperkalaemia. SP084. Nephrol Dial Transplant. 2017; 32.

23. Crnobrnja L, Metlapalli M, Jiang C, Govinna M, Lim AK. The Association of Insulin-Dextrose Treatment with Hypoglycaemia in Patients with Hyperkalaemia. Sci Rep. 2020; 10(1):1–9. https://doi.org/10.1038/s41598-019-56847-4 PMID: 31913322

24. Drevliey B, Gilbert B, Huffman J, Dingman S. 1131: Hypoglycemia After Hyperkalemia Treatment in Emergency Department With or Without Renal Dysfunction. Crit Care Med. 2021; 49(1):567.

25. Dixon D, Goble E, Burridge A, Cox A, Bell C, Fidler B, et al. Reduction of inpatient iatrogenic hypoglycaemia as a result of hyperkalaemia treatment using e-prescribing and multidisciplinary team approach: P190. Diabet Med. 2016; 33.

26. Do AP, Naffouj S, Modi K, Hammoudeh R, Miller MD JB, Dabbagh M. Predictors of Iatrogenic Hypoglycaemia in Treatment of Hyperkalaemia. Available at: https://scholarlycommons.henryford.com/internalmedicine_mtg_abstracts/102/. Accessed February 10, 2022.

27. Driver B. Hypoglycaemia is a Common Complication of Insulin Administration for Treatment of Hyperkalaemia in the ED: 476. Acad Emerg Med. 2016; 23.

28. Farina N, Anderson C. Impact of dextrose dose on hypoglycaemia development following treatment of hyperkalaemia. Ther Adv Drug Saf. 2018; 9(6):323–9. https://doi.org/10.1177/2042098618768725 PMID: 29854393

29. Garcia J, Pintens M, Morris A, Takamoto P, Baumgartner L, Tasaka CL. Reduced versus conventional dose insulin for hyperkalaemia treatment. J Pharm Pract. 2020; 33(3):262–6. https://doi.org/10.1177/0897190018799220 PMID: 30189765

30. Hain M, Fox H, Celmins L, Szwak JA. Effects of Utilization of an Insulin/Dextrose Order Panel for Hyperkalaemia for the Prevention of Hypoglycaemia. Available at: https://accc.confex.com/accc2020aam/mediatfile/Handout/Paper55336/Hain_Effects%20of%20Utilization%20of%20InsulinDextrose%20Order%20Panel%20for%20Hyperkalaemia%20for%20Preventionof%20Hypoglycaemia.pdf. Accessed February 10, 2022.

31. Humphrey T, Torpey N, Hiemstra T. Hyperkalaemia in prevalent kidney transplant recipients. Nephrol Dial Transplant. 2020; 35(suppl. 3): gfaa142.P1655.

32. Humphrey TJ, James G, Wilkinson IB, Hiemstra TF. Clinical outcomes associated with the emergency treatment of hyperkalaemia with intravenous insulin-dextrose. Eur J Intern Med. 2022; 95:87–92. https://doi.org/10.1016/j.ejim.2021.09.018 PMID: 34625340

33. Jacob BC, Peasah SK, Chan HL, Niculas D, Shogbon Nwaesei A. Hypoglycaemia associated with insulin use during treatment of hyperkalaemia among emergency department patients. Hosp Pharm. 2019; 54(3):197–202. https://doi.org/10.1177/018578718779012 PMID: 31205332

34. Keeney KP, Calhoun C, Jennings L, Weeda ER, Weant KA. Assessment of intravenous insulin dosing strategies for the treatment of acute hyperkalaemia in the emergency department. Am J Emerg Med. 2020; 38(6):1082–5. https://doi.org/10.1016/j.ajem.2019.158374 PMID: 31377014

35. Kim H-J. Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalaemia in end-stage renal disease patients. Nephron. 1996; 72(3):476–82. https://doi.org/10.1159/000188917 PMID: 8852501

36. Kocoglu H, Goksu S, Pence S, Soykan B, Kocak T, Yilmaz N. Insulin dose versus rate of potassium decrease in the treatment of hyperkalaemia with iv insulin during extracorporeal circulation: An observational study. Curr Ther Res. 2002; 63(9):549–55.

37. Konowitz N, Bennett S, Binz S, Do A, Hammoudeh R, Naffouj S, et al. Improving the Safety of Insulin Treatment for Hyperkalaemia. Ann Emerg Med. 2019; 74(4):S8–S9.
59. Tee SA, Devine K, Potts A, Javaid U, Razvi S, Quinton R, et al. Iatrogenic hypoglycaemia following glucose-insulin infusions for the treatment of hyperkalaemia. Clin Endocrinol. 2021; 94(2):176–82. https://doi.org/10.1111/cen.14343 PMID: 32979855

60. Tran AV, Rushakoff RJ, Prasad P, Murray SG, Macmaster H. Decreasing hypoglycemia following insulin administration for inpatient hyperkalaemia. J Hosp Med. 2020; 15(2):81–6.

61. Verdier M, DeMott JM, Peksa GD. A comparison of insulin doses for treatment of hyperkalaemia in intensive care unit patients with renal insufficiency. Aust Crit Care. 2021. https://doi.org/10.1016/j.aucc.2021.05.004 PMID: 34167889

62. Wheeler DT, Schafers SJ, Horwede TA, Deal EN, Tobin GS. Weight-based insulin dosing for acute hyperkalaemia results in less hypoglycemia. J Hosp Med. 2016; 11(5):355–7. https://doi.org/10.1002/jhm.2545 PMID: 26762588

63. Williams P, Davenport A, Bone J. Hypoglycaemia following treatment of hyperkalaemia with insulin and dextrose. Postgrad Med J. 1988; 64(747):30–2. https://doi.org/10.1136/pgmj.64.747.30 PMID: 3047719

64. Wu S, Dunn SP, Zorn KE, Anthony SM, Novicoff W, Kirby JL, editors. Risk Factors for Hypoglycemia after Insulin-based Acute Hyperkalemia Treatment. Diabetes. 2015; 64:A605–A606.

65. Yang I, Smalley S, Ahuja T, Merchan C, Smith SW, Papadopoulos J. Assessment of dextrose 50 bolus versus dextrose 10 infusion in the management of hyperkalemia in the ED. Am J Emerg Med. 2020; 38 (3):598–602. https://doi.org/10.1016/j.ajem.2019.09.003 PMID: 31837905

66. Zuern A, Probst LA, Darko W, Rosher P, Miller CD, Gordon L, et al. Effect of a standardized treatment panel on hypoglycaemic events in hospitalized acute hyperkalemic patients treated with intravenous regular insulin. Hosp Pharm. 2020; 55(4):240–5. https://doi.org/10.1177/0018578719841035 PMID: 32742012

67. Mahoney BA, Smith WA, Lo D, Tsoi K, Tonelli M, Clase C. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev. 2005(2): CD003235. https://doi.org/10.1002/14651858.CD003235.pub2 PMID: 15846652

68. Mousavi K, Garcia J, Tellez-Corrales E, Fitter S. Reduced Alternative Insulin Dosing in Hyperkalemia: a Meta-Analysis of Effects on Hypoglycemia and Potassium Reduction. Pharmacotherapy. 2021; 41 (7):598–607. https://doi.org/10.1002/phar.2596 PMID: 33993515

69. Varallo FR, Trombotto V, Lucchetta RC, Mastroianni PdC. Efficacy and safety of the pharmacotherapy used in the management of hyperkalemia: a systematic review. Pharm Pract. 2019; 17(1). https://doi.org/10.18549/PharmPract.2019.1.1361 PMID: 31015873

70. Essack Y, Hoffman M, Rensburg M, Van Wyk J, Meyer C, Erasmus R. A comparison of five glucometers in South Africa. J Endocrinology Metab Diabetes S Afr. 2009; 14(2):102–5.